Peregrine Beats Shareholder Suit Over Lung Cancer Drug

Law360, Washington (August 26, 2013, 6:37 PM EDT) -- A California federal judge tossed a consolidated class action against Peregrine Pharmaceuticals Inc. on Friday, saying the investor plaintiffs didn't adequately allege that the drugmaker and its executives knowingly lied about its lung cancer drug, causing a nosedive of the company's stock price.

According to U.S. District Judge Philip S. Gutierrez, Peregrine and its top brass can't be held liable for securities fraud solely because they failed to verify clinical trial results for one of the company's signature products, bavituximab, an experimental drug for the treatment...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

Nathaniel L Anderson v. Peregrine Pharmaceuticals Inc et al


Case Number

8:12-cv-01647

Court

California Central

Nature of Suit

Securities/Commodities

Judge

Philip S. Gutierrez

Date Filed

September 28, 2012

Law Firms

Companies

Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.